Hillstream Biopharma (NASDAQ:CNTN) Announces Earnings Results

Hillstream Biopharma (NASDAQ:CNTN) released its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, FiscalAI reports.

Hillstream Biopharma Price Performance

Shares of CNTN traded up $0.32 during mid-day trading on Thursday, hitting $3.83. 233,422 shares of the company traded hands, compared to its average volume of 773,060. The stock has a market capitalization of $217.23 million, a PE ratio of -0.96 and a beta of 1.44. The business has a 50-day simple moving average of $3.42. Hillstream Biopharma has a one year low of $1.08 and a one year high of $9.08.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CNTN shares. Wall Street Zen downgraded Hillstream Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Weiss Ratings assumed coverage on Hillstream Biopharma in a report on Monday, March 9th. They set a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Hillstream Biopharma presently has a consensus rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.